Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials

Keyphrases

• Aflibercept 44%
• Anatomic 5%
• Angiopoietin-2 11%
• Best-corrected Visual Acuity 22%
• Central Subfield Thickness 22%
• Change from Baseline 11%
• Clinically Significant 5%
• Diabetic Macular Edema 100%
• Dosing Regimen 11%
• Drug Injection 5%
• Faricimab 100%
• Financial Disclosure 5%
• Footnotes 5%
• Interval Reduction 5%
• Intravitreal 11%
• Non-inferiority 5%
• Number of Injections 5%
• Pathway Inhibitors 5%
• Personalized Treatment 5%
• Phase II Trial 11%
• Rhine 100%
• Safety Profile 5%
• Subretinal Fluid 5%
• Thickness Reduction 5%
• Treat-and-extend 100%
• Treatment Duration 5%
• Vascular Endothelial Growth Factor 11%
• Vascular Stability 5%
• Visual Acuity Change 11%
• Visual Acuity Loss 5%
• Visual Gain 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Aflibercept 44%
• Angiopoietin 2 11%
• Diabetic Macular Edema 100%
• Faricimab 100%
• Vasculotropin A 11%